Last $9.70 USD
Change Today -0.16 / -1.62%
Volume 644.8K
HZNP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

horizon pharma inc (HZNP) Snapshot

Open
$9.84
Previous Close
$9.86
Day High
$9.98
Day Low
$9.53
52 Week High
03/19/14 - $18.30
52 Week Low
08/22/13 - $2.13
Market Cap
725.3M
Average Volume 10 Days
1.2M
EPS TTM
$-1.00
Shares Outstanding
74.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HORIZON PHARMA INC (HZNP)

horizon pharma inc (HZNP) Related Businessweek News

No Related Businessweek News Found

horizon pharma inc (HZNP) Details

Horizon Pharma, Inc., a specialty pharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. Its products include DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA and ankylosing spondylitis (AS). The company also offers RAYOS/LODOTRA, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active RA in adults when accompanied by morning stiffness, as well as for the treatment of polymyalgia rheumatica, psoriatic arthritis, AS, asthma, chronic obstructive pulmonary disease, and various other conditions. Horizon Pharma, Inc. was founded in 2005 and is headquartered in Deerfield, Illinois.

436 Employees
Last Reported Date: 08/7/14
Founded in 2005

horizon pharma inc (HZNP) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $589.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $374.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $396.3K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $376.0K
Compensation as of Fiscal Year 2013.

horizon pharma inc (HZNP) Key Developments

Horizon Pharma Mulls Acquisitions

Horizon Pharma, Inc. (NasdaqGS:HZNP) is seeking acquisitions. Tim Walbert, Chairman, President and Chief Executive Officer, said, "We continue to build our organization both organically and through acquisitions and in licensing opportunities."

Horizon Pharma, Inc. Announces Consolidated Unaudited Earnings Results for Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for Fiscal 2014

Horizon Pharma, Inc. announced consolidated unaudited earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported net sales of $66,062,000, operating loss of $7,100,000, loss before expense for income taxes of $26,889,000, net loss of $27,769,000 or $0.38 per basic and diluted share, adjusted NON GAAP net income of $20,726,000 or $0.21 per diluted share, LBITDA of $14,457,000, adjusted EBITDA of $23,826,000, GAAP cash provided by operating activities of $16,761,000, NON GAAP cash provided by operating activities of $20,130,000, compared to the net sales of $11,131,000, operating loss of $15,804,000, loss before expense for income taxes of $18,792,000, net loss of $18,441,000 or $0.29 per basic and diluted share, adjusted NON GAAP net loss of $15,038,000 or $0.24 per diluted share, LBITDA of $13,564,000, adjusted LBITDA of $12,543,000, GAAP cash used in operating activities of $10,899,000, NON GAAP cash used in operating activities of $10,899,000, for the same quarter a year ago. The company drove $20.1 million of cash flow from operating activities in the quarter. For the year to date, the company reported net sales of $117,988,000, operating loss of $5,513,000, loss before expense for income taxes of $234,244,000, net loss of $234,019,000 or $3.34 per basic and diluted share, adjusted NON GAAP net income of $31,710,000 or $0.34 per diluted share, LBITDA of $212,363,000, adjusted EBITDA of $35,926,000, GAAP cash provided by operating activities of $16,004,000, NON GAAP cash provided by operating activities of $24,468,000, purchase of property and equipment of $1,037,000 compared to the net sales of $19,824,000, operating loss of $34,348,000, loss before expense for income taxes of $41,844,000, net loss of $40,612,000 or $0.65 per basic and diluted share, adjusted NON GAAP net loss of $33,705,000 or $0.54 per diluted share, LBITDA of $31,159,000, adjusted LBITDA of $29,059,000, GAAP cash used operating activities of $33,668,000, NON GAAP cash used in operating activities of $33,668,000, purchase of property and equipment of $345,000 for the same period a year ago. The company announced that it confident in reiterating prior net sales guidance range for fiscal 2014 of $270 to $280 million and adjusted EBITDA range of $80 to $90 million. Preliminary net sales guidance for 2015 in the range of $380 million to $405 million and preliminary adjusted EBITDA guidance of $150 million to $170 million. The Company provided preliminary net revenue guidance for 2015 in the range of $380 million to $405 million and preliminary adjusted EBITDA guidance in the range of $150 million to $170 million, with expectation of September close of the Vidara acquisition.

Horizon Pharma, Inc. to Report Q2, 2014 Results on Aug 07, 2014

Horizon Pharma, Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZNP:US $9.70 USD -0.16

HZNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $14.57 USD -0.18
Pfizer Inc $28.82 USD -0.07
View Industry Companies
 

Industry Analysis

HZNP

Industry Average

Valuation HZNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 9.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON PHARMA INC, please visit www.horizonpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.